{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:30:18Z","timestamp":1791559818775,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fujian Provincial Natural Science Fundation of China","award":["2024J011233"],"award-info":[{"award-number":["2024J011233"]}]},{"name":"Startup Fund for scientific research, Fujian Medical University","award":["2021QH1161"],"award-info":[{"award-number":["2021QH1161"]}]},{"name":"Science and Technology Plan Project of Fuzhou Health System","award":["2023-S-wq9"],"award-info":[{"award-number":["2023-S-wq9"]}]},{"name":"Key Clinical Specialty Discipline Construction Program of Fuzhou, Fujian, P.R.C","award":["20230101"],"award-info":[{"award-number":["20230101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12072-025-10794-7","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:08:22Z","timestamp":1743278902000},"page":"877-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: a multicenter study"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-9264","authenticated-orcid":false,"given":"Qizhen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianji","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"Suppl 1","key":"10794_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4\u201313","journal-title":"Hepatology"},{"issue":"3","key":"10794_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2014.04.032","volume":"61","author":"T Kokudo","year":"2014","unstructured":"Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61(3):583\u2013588","journal-title":"J Hepatol"},{"issue":"1","key":"10794_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12885-019-5870-3","volume":"19","author":"J Lou","year":"2019","unstructured":"Lou J, Li Y, Liang K, et al. Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: a multi-center analysis. BMC Cancer. 2019;19(1):668","journal-title":"BMC Cancer"},{"issue":"6","key":"10794_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.gassur.2005.12.011","volume":"10","author":"YP le Treut","year":"2006","unstructured":"le Treut YP, Hardwigsen J, Ananian P, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10(6):855\u201362","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"10794_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1245\/s10434-012-2646-2","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y, Yuan L, Ge RL, et al. Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: results of a retrospective cohort study. Ann Surg Oncol. 2013;20(3):914\u2013922","journal-title":"Ann Surg Oncol"},{"issue":"10126","key":"10794_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u20131173","journal-title":"Lancet"},{"issue":"12","key":"10794_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(12):1651\u20131659","journal-title":"JAMA Oncol"},{"issue":"8","key":"10794_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen ZR, Huijbers EJM, van Beijnum JR, et al. Anti-angiogenic agents\u2014overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol. 2021;18(8):527\u2013540","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10794_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000528272","volume":"12","author":"M Kudo","year":"2022","unstructured":"Kudo M, Finn RS, Galle PR, et al. IMbrave150: efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 2022;12(3):238\u2013250","journal-title":"Liver Cancer"},{"issue":"7","key":"10794_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u2013990","journal-title":"Lancet Oncol"},{"issue":"10408","key":"10794_CR11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u20131146","journal-title":"Lancet"},{"issue":"3","key":"10794_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u2013693","journal-title":"J Hepatol"},{"key":"10794_CR13","unstructured":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Hepatobiliary cancers, Version 2. 2024. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ hcc.pdf"},{"issue":"3","key":"10794_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","volume":"7","author":"J Zhou","year":"2018","unstructured":"Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 2018;7(3):235\u2013260","journal-title":"Liver Cancer"},{"key":"10794_CR15","doi-asserted-by":"crossref","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4): 583\u2013705","DOI":"10.3350\/cmh.2022.0294"},{"issue":"5","key":"10794_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T, et al. Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53(5):383\u2013390","journal-title":"Hepatol Res"},{"issue":"16","key":"10794_CR17","doi-asserted-by":"publisher","first-page":"16805","DOI":"10.1002\/cam4.6302","volume":"12","author":"X Li","year":"2023","unstructured":"Li X, Ding X, Liu M, et al. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus. Cancer Med. 2023;12(16):16805\u201316814","journal-title":"Cancer Med"},{"issue":"1","key":"10794_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1186\/s12885-024-12484-3","volume":"24","author":"Z Tang","year":"2024","unstructured":"Tang Z, Bai T, Wei T, et al. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study. BMC Cancer. 2024;24(1):717","journal-title":"BMC Cancer"},{"issue":"67","key":"10794_CR19","volume":"12","author":"XK Wu","year":"2023","unstructured":"Wu XK, Yang LF, Chen YF, et al. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine. 2023;12(67): 102367","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10794_CR20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.acra.2023.09.001","volume":"31","author":"JX Zhang","year":"2024","unstructured":"Zhang JX, Hua HJ, Cheng Y, et al. Role of transarterial chemoembolization in the era of tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy for unresectable hepatocellular carcinoma: a retrospective propensity score matched analysis. Acad Radiol. 2024;31(4):1304\u20131311","journal-title":"Acad Radiol"},{"issue":"4","key":"10794_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203\u2013217","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"10794_CR22","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498-509","journal-title":"Lancet Oncol"},{"issue":"10","key":"10794_CR23","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2147\/JHC.S432542","volume":"9","author":"G Li","year":"2023","unstructured":"Li G, Zhao Y, Li K, et al. Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: real-world data from a tertiary centre. J Hepatocell Carcinoma. 2023;9(10):2037\u20132048","journal-title":"J Hepatocell Carcinoma"},{"issue":"5","key":"10794_CR24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.ijrobp.2023.07.001","volume":"118","author":"C Ning","year":"2024","unstructured":"Ning C, Zhang X, Wang Y, et al. Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2024;118(5):1461\u20131471","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10794_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.21037\/hbsn.2019.10.07","volume":"9","author":"ZH Chen","year":"2020","unstructured":"Chen ZH, Wang K, Zhang XP, et al. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 2020;9(6):717\u2013728","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"10794_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","volume":"18","author":"J Shi","year":"2011","unstructured":"Shi J, Lai EC, Li N, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci. 2011;18(1):74\u201380","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"10794_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288\u2013306","journal-title":"J Hepatol"},{"issue":"4","key":"10794_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/HEP.0000000000000776","volume":"80","author":"M Zhu","year":"2024","unstructured":"Zhu M, Liu Z, Chen S, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter, single-arm, phase 2 study. Hepatology. 2024;80(4):807\u2013815","journal-title":"Hepatology"},{"key":"10794_CR29","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: Nov 27."},{"issue":"4","key":"10794_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1037\/met0000446","volume":"28","author":"M Suero","year":"2023","unstructured":"Suero M, Botella J, Dur\u00e1n JI. Methods for estimating the sampling variance of the standardized mean difference. Psychol Methods. 2023;28(4):895\u2013904","journal-title":"Psychol Methods"},{"issue":"28","key":"10794_CR31","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u20133679","journal-title":"Stat Med"},{"issue":"4","key":"10794_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/hepr.13297","volume":"49","author":"ZH Chen","year":"2019","unstructured":"Chen ZH, Zhang XP, Wang K, et al. Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: a propensity score matching analysis. Hepatol Res. 2019;49(4):441\u2013452","journal-title":"Hepatol Res"},{"issue":"1","key":"10794_CR33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s12885-019-5654-9","volume":"19","author":"TH Pao","year":"2019","unstructured":"Pao TH, Hsueh WT, Chang WL, et al. Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma. BMC Cancer. 2019;19(1):560","journal-title":"BMC Cancer"},{"issue":"6","key":"10794_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/09553002.2020.1721607","volume":"96","author":"CH Rim","year":"2020","unstructured":"Rim CH, Jeong BK, Kim TH, et al. Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and\/or right atrium involvement: a multicenter trial in Korea (KROG 17\u201310). Int J Radiat Biol. 2020;96(6):759\u2013766","journal-title":"Int J Radiat Biol"},{"issue":"24","key":"10794_CR35","doi-asserted-by":"publisher","first-page":"e2102611118","DOI":"10.1073\/pnas.2102611118","volume":"118","author":"DM Lussier","year":"2021","unstructured":"Lussier DM, Alspach E, Ward JP, et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci USA. 2021;118(24):e2102611118","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10794_CR36","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","volume":"16","author":"C Faivre-Finn","year":"2021","unstructured":"Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860\u2013867","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10794_CR37","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(9):1276\u20131282","journal-title":"JAMA Oncol"},{"issue":"6","key":"10794_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1159\/000368010","volume":"32","author":"YG Suh","year":"2014","unstructured":"Suh YG, Lee EJ, Cha H, et al. Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy. Dig Dis. 2014;32(6):725\u2013732","journal-title":"Dig Dis"},{"issue":"5","key":"10794_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u2013340","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10794_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13014-023-02270-z","volume":"18","author":"X Ji","year":"2023","unstructured":"Ji X, Xu Z, Sun J, et al. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiat Oncol. 2023;18(1):101","journal-title":"Radiat Oncol"},{"issue":"1","key":"10794_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.21037\/hbsn-23-619","volume":"13","author":"J Yang","year":"2024","unstructured":"Yang J, Shui Y, Liu L, et al. Insights into treatment for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium. Hepatobiliary Surg Nutr. 2024;13(1):168\u2013171","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"11","key":"10794_CR42","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/hepr.12657","volume":"46","author":"XL Li","year":"2016","unstructured":"Li XL, Guo WX, Hong XD, et al. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Hepatol Res. 2016;46(11):1088\u20131098","journal-title":"Hepatol Res"},{"issue":"1","key":"10794_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/liv.13191","volume":"37","author":"JH Im","year":"2017","unstructured":"Im JH, Yoon SM, Park HC, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int. 2017;37(1):90\u2013100","journal-title":"Liver Int"},{"issue":"12","key":"10794_CR44","doi-asserted-by":"publisher","first-page":"888755","DOI":"10.3389\/fonc.2022.888755","volume":"11","author":"JI Yu","year":"2022","unstructured":"Yu JI, Kang W, Yoo GS, et al. Safety and efficacy of liver-directed radiotherapy in combination with lenvatinib for hepatocelluar carcinoma with macroscopic tumor thrombosis. Front Oncol. 2022;11(12):888755","journal-title":"Front Oncol"},{"issue":"5","key":"10794_CR45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jhep.2021.11.013","volume":"76","author":"D D'Avola","year":"2022","unstructured":"D\u2019Avola D, Granito A, Torre-Al\u00e1ez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185\u20131198","journal-title":"J Hepatol"},{"issue":"2","key":"10794_CR46","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S1470-2045(16)30569-1","volume":"18","author":"A Granito","year":"2017","unstructured":"Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncol. 2017;18(2):e101\u2013e112","journal-title":"Lancet Oncol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10794-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:01:53Z","timestamp":1757152913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10794-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10794"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10794-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}